Atherosclerosis and Hypertension Research Group, Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy.
Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy.
Angiology. 2020 Mar;71(3):217-225. doi: 10.1177/0003319719889428. Epub 2019 Nov 25.
Results of previous clinical trials evaluating the effect of pycnogenol supplementation on blood pressure (BP) are controversial. Therefore, we aimed to assess the impact of pycnogenol on BP through a systematic review of literature and meta-analysis of available randomized, double-blind, placebo-controlled clinical studies (randomized clinical trials [RCTs]). Literature search included SCOPUS, PubMed-Medline, ISI Web of Science, and Google Scholar databases up to January 10, 2019 to identify RCTs investigating the impact of pycnogenol on BP. Two investigators independently extracted data on study characteristics, methods, and outcomes. This systematic review and meta-analysis is registered in International Prospective Register of Systematic Reviews (PROSPERO) under number CRD42018112172. Overall, the impact of pycnogenol on BP was reported in 7 trials involving 626 participants. Meta-analysis did not suggest any significant improvement in systolic BP (weighted mean difference [WMD]: -0.028 mm Hg; 95% confidence interval [CI]: -0.182 to 0.127; = .726; = 46%), diastolic BP (WMD: -0.144 mm Hg; 95% CI: -0.299 to 0.010; = .067; = 0%), mean arterial pressure (WMD: -0.091 mm Hg; 95% CI: -0.246 to 0.063; = .246; = 0%), and pulse pressure (WMD: -0.003 mm Hg; 95% CI: -0.151 to 0.158; = .966; = 0%) following pycnogenol treatment. Results persisted in the leave-one-out sensitivity analysis. Therefore, the present meta-analysis does not suggest any significant effect of pycnogenol on BP.
先前评估碧萝芷补充剂对血压（BP）影响的临床试验结果存在争议。因此，我们旨在通过系统评价文献和荟萃分析现有随机、双盲、安慰剂对照的临床研究（随机对照试验[RCT]）来评估碧萝芷对 BP 的影响。文献检索包括 SCOPUS、PubMed-Medline、ISI Web of Science 和 Google Scholar 数据库，截至 2019 年 1 月 10 日，以确定调查碧萝芷对 BP 影响的 RCT。两名研究者独立提取研究特征、方法和结局的数据。本系统评价和荟萃分析已在国际前瞻性注册系统评价（PROSPERO）中注册，注册号为 CRD42018112172。总体而言，有 7 项试验报告了碧萝芷对 BP 的影响，涉及 626 名参与者。荟萃分析表明，收缩压（WMD：-0.028mmHg；95%置信区间[CI]：-0.182 至 0.127； =.726； = 46%）、舒张压（WMD：-0.144mmHg；95% CI：-0.299 至 0.010； =.067； = 0%）、平均动脉压（WMD：-0.091mmHg；95% CI：-0.246 至 0.063； =.246； = 0%）和脉压（WMD：-0.003mmHg；95% CI：-0.151 至 0.158； =.966； = 0%）在碧萝芷治疗后均无显著改善。在逐一剔除敏感分析中结果仍持续。因此，本荟萃分析表明碧萝芷对 BP 无显著影响。
